−5.5%
since Oct 1
The idea
I believe medicine in 2045 will look fundamentally different: genes get edited instead of symptoms managed, AI designs drugs instead of years of trial and error, and blood tests catch cancer early instead of late. About a quarter of this basket sits in steady tools and equipment makers who get paid regardless of which cure wins, while smaller positions spread across gene editing, AI drug discovery, and early detection. I expect most of those smaller bets to disappoint, but the idea only needs a few to work, since a real cure doesn't just boost a stock, it creates a new industry.
What it owns
- Companies that supply instruments, reagents, manufacturing services, and analytical equipment to biotech and pharma regardless of which specific drugs succeed. · Thermo Fisher ScientificIt sells instruments, reagents, and manufacturing services to nearly every biotech and pharma company, so it collects revenue whichever cure wins., DanaherIt supplies equipment and consumables used to manufacture biologic drugs, gene therapies, and diagnostics, getting paid on production volume regardless of which drug succeeds., West Pharmaceutical ServicesIt makes the stoppers, seals, and delivery components for injectable drugs, including nearly every biologic, so it gets paid per dose regardless of whose drug it is., IlluminaIts machines drove the cost of reading a genome from millions of dollars toward a hundred, and cheap sequencing underpins everything else in this basket., Agilent TechnologiesIt sells analytical instruments and lab services across pharma and diagnostics, a position in research tools spending by drug developers., 10x GenomicsIt sells instruments that let researchers read biology one cell at a time, the resolution gene editing and AI discovery both need to work.28%
- Companies developing genetic medicines, gene therapies, and base editing approaches to treat previously intractable diseases. · Vertex PharmaceuticalsIt has already turned cystic fibrosis from a death sentence into a managed condition and brought the first approved CRISPR gene therapy to market with Casgevy., Regeneron PharmaceuticalsIt built its pipeline on one of the world's largest human genetic databases, exactly the gene-first medicine this take expects., CRISPR TherapeuticsIt has already gotten Casgevy approved for sickle cell and beta thalassemia, proving that editing genes in patients actually works., Intellia TherapeuticsIt edits genes inside the patient's body with a single infusion, no cell extraction needed, which is the harder and broader version of approved gene therapy., ARK Genomic Revolution ETFIt spreads the genomic medicine bet across dozens of smaller companies this take doesn't hold directly, so a breakthrough from an unexpected player still gets captured., Beam TherapeuticsIts base editing changes a single DNA letter without cutting the strand, in principle safer and more precise than first-generation CRISPR approaches.27%
- Companies using artificial intelligence, computational biology, and high-throughput screening to design drugs and find targets faster than traditional methods. · NVIDIAEvery AI drug discovery effort runs on its chips, so it taxes the whole AI-designed-drugs trend without betting on any single pipeline., Tempus AIIt turns real patient records and genomic data into the training material AI drug discovery needs, then sells that data to pharma., Recursion PharmaceuticalsIt runs millions of automated cell experiments and trains AI on the results to find drugs humans would miss, backed by NVIDIA computing power., SchrodingerIts software simulates how molecules behave before anyone synthesizes them, letting drug discovery happen by computation instead of trial and error.16%
- Companies rebuilding how care is delivered through robotics, continuous monitoring, and automation that lets patients manage conditions in real time. · Intuitive SurgicalIts da Vinci robots are the default platform for minimally invasive surgery, and each installed system generates recurring instrument revenue for years., DexComIts continuous glucose monitors replace finger sticks with a live data stream, rebuilding care delivery around real-time information instead of periodic checks., InsuletIts Omnipod pairs with glucose monitors to automate insulin dosing, effectively an artificial pancreas worn on the skin instead of a tethered pump.13%
- Companies developing blood tests and non-invasive screening to catch cancer and disease recurrence months earlier than conventional imaging. · NateraIts Signatera test finds traces of cancer in blood after treatment, catching recurrence months before a scan would., Guardant HealthIts Shield blood test screens for colorectal cancer with a simple draw instead of a colonoscopy, catching disease earlier and non-invasively.8%
- Cash8%